ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · Real-Time Price · USD
90.60
-1.33 (-1.45%)
At close: Oct 31, 2025, 4:00 PM EDT
91.00
+0.40 (0.44%)
After-hours: Oct 31, 2025, 5:57 PM EDT
ANI Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts that cover ANI Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $99.14, which forecasts a 9.43% increase in the stock price over the next year. The lowest target is $80 and the highest is $121.
Price Target: $99.14 (+9.43%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ANI Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 3 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 9 | 9 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Hold Maintains $77 → $90 | Hold | Maintains | $77 → $90 | -0.66% | Oct 9, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $95 → $115 | Buy | Maintains | $95 → $115 | +26.93% | Sep 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $93 → $121 | Strong Buy | Maintains | $93 → $121 | +33.55% | Sep 17, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $86 → $114 | Strong Buy | Maintains | $86 → $114 | +25.83% | Sep 8, 2025 |
| Truist Securities | Truist Securities | Hold Maintains $65 → $77 | Hold | Maintains | $65 → $77 | -15.01% | Aug 11, 2025 |
Financial Forecast
Revenue This Year
860.04M
from 614.38M
Increased by 39.99%
Revenue Next Year
942.31M
from 860.04M
Increased by 9.57%
EPS This Year
7.42
from -1.04
EPS Next Year
8.16
from 7.42
Increased by 9.98%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 914.7M | 1.0B | |||
| Avg | 860.0M | 942.3M | |||
| Low | 813.2M | 876.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 48.9% | 20.9% | |||
| Avg | 40.0% | 9.6% | |||
| Low | 32.4% | 1.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7.79 | 9.24 | |||
| Avg | 7.42 | 8.16 | |||
| Low | 6.93 | 7.19 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 24.5% | |||
| Avg | - | 10.0% | |||
| Low | - | -3.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.